title: Assessment of metabolic control in patients with diabetes treated with insulin using Contour USB and A1cNow+ devices (COMET study).
abstract: OBJECTIVE
  The self-determination of blood glucose is relevant for diabetes mellitus (DM) insulin-treated patients. The use of glucometers with advanced features and measuring glycated haemoglobin (HbA1c) may help improve metabolic control. The main objective of this study was to determine the percentage of insulin treated patients who reduced HbA1c by at least 0.4% after 6 months of using Contour and A1CNow+.
  
  
  METHODS
  Observational, prospective, multicentre study in adult DM insulin treated patients, with HbA1c> 8%.
  
  
  RESULTS
  Of the 454 recruited patients analysed, a total of 333 were evaluable. After 6 months the HbA1c decreased (P<.05) in both groups [-0.89 (95% CI -1.01 to -0.76) and -0.98 (95% CI: -1.21 to -0.76), in type 1 and 2 DM, respectively]. An HbA1c reduction of 0.4% was observed in 73% of patients after 6 months of device use. A decrease in the number of patients with HbA1c > 8% was observed, with this reaching: 41% for all, 45% in type 1 DM, and 25% in type 2 DM. In the glycaemic profile, a reduction (P<.05) was observed in pre- and post-prandial glycaemia in both groups (-20.7±36.4 and -37.1±47.1mg/dL, respectively), with 23% pre-prandial glucose < 130mg/dL and post-prandial < 180mg/dL CONCLUSION: The use of glucometers with advanced features, and measuring glycated haemoglobin (HbA1c) may help improve metabolic control and to monitor insulin treated DM patients more closely.
authors.affiliation: Unidad de Diabetes, Endocrinología y Nutrición, Hospital Clínic i Universitari, Barcelona, España. Electronic address: ivinagre@clinic.ub.es.
authors.forename: Irene
authors.initials: I
authors.lastname: Vinagre
authors.affiliation: Bayer Hispania S.L., Barcelona, España.
authors.forename: Pilar
authors.initials: P
authors.lastname: Álvarez
authors.affiliation: Bayer Hispania S.L., Barcelona, España.
authors.forename: Nicolás
authors.initials: N
authors.lastname: García
authors.affiliation: Adknoma Health Research S.L., Barcelona, España.
authors.forename: Guillem
authors.initials: G
authors.lastname: Roura
authors.affiliation: Unidad de Diabetes, Endocrinología y Nutrición, Hospital Clínic i Universitari, Barcelona, España.
authors.forename: Ignacio
authors.initials: I
authors.lastname: Conget
mesh_terms: D000328:Adult; D000428:Alcohol Drinking / Q000453:epidemiology; D001786:Blood Glucose / Q000032:analysis*; D015190:Blood Glucose Self-Monitoring / Q000295:instrumentation* / Q000379:methods; D048909:Diabetes Complications / Q000453:epidemiology; D003922:Diabetes Mellitus, Type 1 / Q000097:blood* / Q000188:drug therapy; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy; D005215:Fasting / Q000097:blood; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000453:epidemiology; D019518:Postprandial Period; D011446:Prospective Studies; D012907:Smoking / Q000453:epidemiology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin
keywords: Control metabólico; Diabetes; Glycated haemoglobin; Hemoglobina glucosilada; Metabolic control